These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 17637812)

  • 1. Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML.
    Martelli MP; Manes N; Pettirossi V; Liso A; Pacini R; Mannucci R; Zei T; Bolli N; di Raimondo F; Specchia G; Nicoletti I; Martelli MF; Falini B
    Leukemia; 2008 Jan; 22(1):195-8. PubMed ID: 17637812
    [No Abstract]   [Full Text] [Related]  

  • 2. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.
    Bolli N; De Marco MF; Martelli MP; Bigerna B; Pucciarini A; Rossi R; Mannucci R; Manes N; Pettirossi V; Pileri SA; Nicoletti I; Falini B
    Leukemia; 2009 Mar; 23(3):501-9. PubMed ID: 19005479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.
    Falini B; Sportoletti P; Martelli MP
    Curr Opin Oncol; 2009 Nov; 21(6):573-81. PubMed ID: 19770764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia.
    Falini B; Mecucci C; Saglio G; Lo Coco F; Diverio D; Brown P; Pane F; Mancini M; Martelli MP; Pileri S; Haferlach T; Haferlach C; Schnittger S
    Haematologica; 2008 Mar; 93(3):439-42. PubMed ID: 18268276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
    Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
    Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
    Falini B; Nicoletti I; Martelli MF; Mecucci C
    Blood; 2007 Feb; 109(3):874-85. PubMed ID: 17008539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML.
    Falini B; Bigerna B; Pucciarini A; Tiacci E; Mecucci C; Morris SW; Bolli N; Rosati R; Hanissian S; Ma Z; Sun Y; Colombo E; Arber DA; Pacini R; La Starza R; Verducci Galletti B; Liso A; Martelli MP; Diverio D; Pelicci PG; Lo Coco F; Martelli MF
    Leukemia; 2006 Feb; 20(2):368-71. PubMed ID: 16341033
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
    Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
    Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia.
    Scholl S; Mügge LO; Landt O; Loncarevic IF; Kunert C; Clement JH; Höffken K
    Leuk Res; 2007 Sep; 31(9):1205-11. PubMed ID: 17306368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
    Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
    Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
    Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
    Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
    Falini B
    Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia.
    Noguera NI; Ammatuna E; Zangrilli D; Lavorgna S; Divona M; Buccisano F; Amadori S; Mecucci C; Falini B; Lo-Coco F
    Leukemia; 2005 Aug; 19(8):1479-82. PubMed ID: 15973451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoplasmic expression of nucleophosmin 1 as a marker for diagnosing residual disease of acute myeloid leukemia.
    Dai Q; Ren Y
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):205-11. PubMed ID: 23591014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunohistochemical demonstration of mutant nucleophosmin in acute myeloid leukemia: biological and clinical features related to NPMc expression].
    Bedekovics J; Rejto L; Telek B; Udvardy M; Ujfalusi A; Oláh E; Hevessy Z; Kappelmayer J; Kajtár B; Méhes G
    Orv Hetil; 2009 May; 150(22):1031-5. PubMed ID: 19465351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population.
    Ahmad F; Mandava S; Das BR
    Hematol Oncol; 2009 Jun; 27(2):90-7. PubMed ID: 19365794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.
    Gorello P; Cazzaniga G; Alberti F; Dell'Oro MG; Gottardi E; Specchia G; Roti G; Rosati R; Martelli MF; Diverio D; Lo Coco F; Biondi A; Saglio G; Mecucci C; Falini B
    Leukemia; 2006 Jun; 20(6):1103-8. PubMed ID: 16541144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
    Falini B; Martelli MP; Mecucci C; Liso A; Bolli N; Bigerna B; Pucciarini A; Pileri S; Meloni G; Martelli MF; Haferlach T; Schnittger S
    Haematologica; 2008 May; 93(5):775-9. PubMed ID: 18367491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partner.
    Dupret C; Asnafi V; Leboeuf D; Millien C; Ben Abdelali R; Preudhomme C; Beldjord K; Delabesse E; Macintyre E
    Leukemia; 2005 Dec; 19(12):2337-8. PubMed ID: 16304577
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid flow cytometric detection of aberrant cytoplasmic localization of nucleophosmin (NPMc) indicating mutant NPM1 gene in acute myeloid leukemia.
    Oelschlaegel U; Koch S; Mohr B; Schaich M; Falini B; Ehninger G; Thiede C
    Leukemia; 2010 Oct; 24(10):1813-6. PubMed ID: 20724983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.